Quince Therapeutics, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. Quince is a preclinical-stage biopharmaceutical company and has not generated meaningful product revenue or achieved profitability.
Financial performance and position
| Metric | Q1 2023 | Q1 2022 / comparison |
|---|---|---|
| Revenue | $6,000 reported in acquisition-related disclosure; no meaningful product revenue | $0 |
| Research and development expense | $3.23 million | $12.76 million, down 74.7% |
| General and administrative expense | $3.83 million | $9.11 million, down 58.0% |
| Intangible asset impairment | $5.90 million | None |
| Net loss | $12.25 million | $21.64 million |
| Net loss per share | $0.34 | $0.72 |
| Net cash used in operations | $3.57 million | $16.09 million |
| Cash and cash equivalents | $46.71 million | $44.58 million at Dec. 31, 2022 |
| Short-term investments | $43.49 million | $45.60 million at Dec. 31, 2022 |
| Total liabilities | $3.12 million | $3.32 million at Dec. 31, 2022 |
Including $0.48 million of long-term investments, cash, cash equivalents and investments totaled approximately $90.7 million at quarter-end. Current assets were $92.5 million versus current liabilities of $3.1 million. The filing reports no material borrowings; lease obligations remain. Gross margin is not meaningful for this development-stage company.
Operating expenses declined substantially, mainly due to the wind-down or sale of legacy programs and lower headcount and stock-based compensation. The $5.9 million NOV004 intangible impairment was non-cash. Higher interest income partly offset expenses. The operating cash outflow was lower than net loss largely because of non-cash charges, including the impairment.
Strategy, changes and outlook
- In January 2023, Quince shifted priorities to seeking in-licenses or acquisitions of clinical-stage assets for debilitating and rare diseases. It plans to out-license its bone-targeting platform and NOV004, whose internal development it discontinued.
- The company sold its legacy protease-inhibitor portfolio to Lighthouse Pharmaceuticals in January. Consideration included a 7.5% equity interest and potential milestone payments of up to $150 million, plus royalties and certain sublicense income. These contingent amounts depend on future development, approvals and sales and are not guaranteed.
- Quince reduced its workforce by approximately 47%; the reduction was completed in April 2023. It estimated approximately $0.4 million of related expenses, mostly cash severance, and noted other possible restructuring costs.
- Management stated that existing resources could fund planned operations into at least 2026, excluding costs associated with in-licensing activities. Separately, the financial-statement note says cash, cash equivalents and short-term investments were expected to fund planned operations for at least 12 months from issuance. If Quince successfully in-licenses or acquires a clinical-stage asset, management anticipates needing substantial additional capital.
- On April 5, 2023, the board adopted a stockholder rights plan, effective April 17 and scheduled to expire April 5, 2024 unless earlier redeemed or exchanged. The company also said it retained a financial advisor to support evaluation of strategic alternatives.
Risks and unusual items
- Quince has a $300.5 million accumulated deficit, ongoing losses and no approved or currently advancing drug candidate. Its strategy depends on successfully identifying and funding new assets; the company may need to delay or reduce plans if financing is unavailable on acceptable terms.
- It may not find a partner for NOV004 or realize material value from the Lighthouse shares or contingent payments. Lighthouse is a private, early-stage company, and its shares have no established public market.
- Available-for-sale investments had $331,000 of gross unrealized losses at March 31, 2023; the company reported no impairment or credit losses. Management also disclosed that cash balances at financial institutions can exceed FDIC insurance limits.
- The filing describes a related-party transaction with Morphimmune: Quince sold lab equipment for $80,000 and entered a sublease expected to generate approximately $57,000 over its term. The CEO was an investor in Morphimmune; a former director was its co-founder and board member.
- The filing says Quince regained Nasdaq’s minimum bid-price compliance in April 2023, but continued listing compliance is not assured. The rights plan and other governance provisions may affect potential changes of control.
Important facts for investors to verify
- Reconcile the stated runway: the filing gives both “at least 12 months” and “into at least 2026,” with the latter explicitly excluding in-licensing costs.
- Track cash burn and spending after the workforce reduction, and determine whether new financing will be needed to pursue acquisitions or in-licenses.
- Confirm whether Quince secures a partner for NOV004 and whether any Lighthouse milestones, royalties or sublicense payments become payable or collectible.
- Review the impact and terms of the rights plan and the outcome of the board’s strategic-alternatives review.
- Assess the status of Nasdaq listing compliance, as well as any additional restructuring or lease-related costs.